An IPO So Nice REGENXBIO Will Try It Twice

REGENXBIO Inc. is hoping to build on the success of its IPO – and investor enthusiasm for gene therapy in general – by taking its liver disease-focused spinout, Dimension Therapeutics Inc., public as well.